CoChat

STING promotes CD8 T-cell cardiotropism and fibrosis from distinct cellular compartments in doxorubicin cardiomyopathy

Bayer, Abraham L, Zambrano, Maria Antonia, Emig, Ramona, Sanders, Erin, Smolgovsky, Sasha, Wagner, Noah, Bedi, Kenneth C, Bhave, Shreyas, Kapur, Navin K, Margulies, Kenneth B, Asnani, Aarti, Alcaide, Pilar · 2026 · Cardiovascular Research
Cited by 3

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Aims: Doxorubicin (DR), a widely prescribed chemotherapy, has an unfortunate side effect of cardiotoxicity resulting from DNA damage and cardiac cell death. Cardiac atrophy, fibrosis and a cytotoxic CD8+ T-cell response, alongside increased cardiac and circulating interferon-inducible chemokines are hallmarks for DR cardiotoxicity. Methods and results: We discovered that the activation of the stimulator of interferon genes (STING) in several distinct cardiac cell compartments is central to CD8+ T-cell cardiotropism and DR cardiotoxicity. DR activates STING in cardiac fibroblasts, endothelial cells (ECs), and myeloid cells in vivo and in vitro. Myeloid STING is required for CD8+ T-cell activation and cardiotropism, whereas EC-STING mediates CD8+ T-cell cardiotropism towards CXCL9/10 and transendothelial migration. In contrast, cardiac fibroblast STING is dispensable for the cardiac CD8+ T-cell immune response but drives fibroblast transformation. We report CXCR3+ T cells and CXCL9/CXCL10 are more abundant in the hearts of DR cardiotoxicity patients. Conclusion: Our work positions STING as a cell-specific driver of CD8+ T-cell cardiac inflammation and fibroblast activation in DR cardiotoxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cvr/cvag098

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 35

  1. Sritharan, 2021, A comprehensive review on time-tested anticancer drug doxorubicin, Life Sci, 278, 119527, 10.1016/j.lfs.2021.119527 · DOI · Paper page
  2. Henriksen, 2018, Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention, Heart, 104, 971, 10.1136/heartjnl-2017-312103 · DOI · Paper page
  3. Nitiss, 2009, Targeting DNA topoisomerase II in cancer chemotherapy, Nat Rev Cancer, 9, 338, 10.1038/nrc2607 · DOI · Paper page
  4. Kim, 2006, Doxorubicin-induced reactive oxygen species generation and intracellular Ca2 + increase are reciprocally modulated in rat cardiomyocytes, Exp Mol Med, 38, 535, 10.1038/emm.2006.63 · DOI · Paper page
  5. Bayer, 2024, Cytotoxic T cells drive doxorubicin-induced cardiac fibrosis and systolic dysfunction, Nat Cardiovasc Res, 3, 970, 10.1038/s44161-024-00507-y · DOI
  6. Christidi, 2021, Regulated cell death pathways in doxorubicin-induced cardiotoxicity, Cell Death Dis, 12, 1, 10.1038/s41419-021-03614-x · DOI · Paper page
  7. Upshaw, 2024, Dexrazoxane to prevent cardiotoxicity in adults treated with anthracyclines, JACC CardioOncol, 6, 322, 10.1016/j.jaccao.2024.02.004 · DOI · Paper page
  8. Macedo, 2019, Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer, JACC CardioOncol, 1, 68, 10.1016/j.jaccao.2019.08.003 · DOI · Paper page
  9. Decout, 2021, The cGAS–STING pathway as a therapeutic target in inflammatory diseases, Nat Rev Immunol, 21, 548, 10.1038/s41577-021-00524-z · DOI · Paper page
  10. Anastasiou, 2021, Endothelial STING controls T cell transmigration in an IFN-I dependent manner, JCI Insight, 6, e149346, 10.1172/jci.insight.149346 · DOI
  11. Shamseddine, 2022, Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies, J Exp Med, 220, e20220809, 10.1084/jem.20220809 · DOI
  12. Luo, 2023, Critical role of the cGAS-STING pathway in doxorubicin-induced cardiotoxicity, Circ Res, 132, e223, 10.1161/CIRCRESAHA.122.321587 · DOI · Paper page
  13. Lei, 2023, Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity, Cell, 186, 3013, 10.1016/j.cell.2023.05.039 · DOI · Paper page
  14. Jin, 2011, MPYS is required for IRF3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers c-di-AMP and c-di-GMP, J Immunol, 187, 2595, 10.4049/jimmunol.1100088 · DOI · Paper page
  15. Sanders, 2025, Endothelial cell stimulator of i genes regulates IL-6 production and is required for pathologic cardiac hypertrophy and contractile dysfunction in experimental heart failure, Am J Pathol, 195, 1788, 10.1016/j.ajpath.2025.06.004 · DOI
  16. Pham, 2025, Opposing roles for myeloid and smooth muscle cell STING in pulmonary hypertension, JCI Insight, 10, 10.1172/jci.insight.184792 · DOI
  17. Ngwenyama, 2022, Antigen presentation by cardiac fibroblasts promotes cardiac dysfunction, Nat Cardiovasc Res, 1, 761, 10.1038/s44161-022-00116-7 · DOI · Paper page
  18. Ngwenyama, 2019, CXCR3 regulates CD4+ T cell cardiotropism in pressure overload–induced cardiac dysfunction, JCI Insight, 4, e125527, 10.1172/jci.insight.125527 · DOI · Paper page
  19. Luscinskas, 1989, Endothelial-leukocyte adhesion molecule-1-dependent and leukocyte (CD11/CD18)-dependent mechanisms contribute to polymorphonuclear leukocyte adhesion to cytokine-activated human vascular endothelium, J Immunol, 142, 2257, 10.4049/jimmunol.142.7.2257 · DOI · Paper page
  20. Bayer, 2023, T-cell MyD88 is a novel regulator of cardiac fibrosis through modulation of T-cell activation, Circ Res, 133, 412, 10.1161/CIRCRESAHA.123.323030 · DOI
  21. Chen, 2018, Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure, Nat Med, 24, 1225, 10.1038/s41591-018-0046-2 · DOI · Paper page
  22. Liu, 2026, An integrated approach using CITE-sequencing and plasma proteomics reveals immune signatures of doxorubicin cardiotoxicity, Circulation
  23. Huang, 2025, Novel therapeutic approach targeting CXCR3 to treat immunotherapy myocarditis, Circ Res, 136, 473, 10.1161/CIRCRESAHA.124.325652 · DOI
  24. Clausen, 1999, Conditional gene targeting in macrophages and granulocytes using LysMcre mice, Transgenic Res, 8, 265, 10.1023/A:1008942828960 · DOI · Paper page
  25. Farber, 1997, Mig and IP-10: CXC chemokines that target lymphocytes, J Leukoc Biol, 61, 246, 10.1002/jlb.61.3.246 · DOI · Paper page
  26. Guo, 2025, Human single-nucleus RNA sequencing identifies CD47 as a therapeutic target for doxorubicin-induced cardiomyopathy, Circulation, 152, 661, 10.1161/CIRCULATIONAHA.124.071217 · DOI
  27. Lucero, 2026, Cardiomyocyte β-arrestins mediate inflammation and cGAS-STING activation in CVB3 viral myocarditis, Am J Physiol Heart Circ Physiol, 330, H499, 10.1152/ajpheart.00589.2025 · DOI
  28. Wahyuni, 2022, CXCL10 is a novel anti-angiogenic factor downstream of p53 in cardiomyocytes, Physiol Rep, 10, e15304, 10.14814/phy2.15304 · doi:10.14814/phy2.15304
  29. Corbera-Bellalta, 2016, Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis, Ann Rheum Dis, 75, 1177, 10.1136/annrheumdis-2015-208371 · DOI
  30. Liu, 2012, Endoplasmic Reticulum stress regulates the innate immunity critical transcription factor IRF3, J Immunol, 189, 4630, 10.4049/jimmunol.1102737 · DOI · Paper page
  31. Paludan, 2013, Immune sensing of DNA, Immunity, 38, 870, 10.1016/j.immuni.2013.05.004 · DOI · Paper page
  32. de Graaf, 2018, NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid, Hepatol Commun, 2, 492, 10.1002/hep4.1170 · DOI · Paper page
  33. 2012, A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis, Arthritis Rheum, 64, 1730, 10.1002/art.34330 · DOI · Paper page
  34. Christen, 2023, Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetes, Clin Exp Immunol, 214, 131, 10.1093/cei/uxad083 · DOI
  35. Shengchao, 2024, Long-term CXCR3 antagonist AMG487 mitigated acute graft-versus-host disease by inhibiting T cell activation in a murine model, Transpl Immunol, 87, 102128, 10.1016/j.trim.2024.102128 · doi:10.1016/j.trim.2024.102128

Metadata

Authors
Bayer, A. L., Zambrano, M. A., Emig, R., Sanders, E., Smolgovsky, S., Wagner, N., Bedi, K. C., Bhave, S., Kapur, N. K., Margulies, K. B., Asnani, A., & Alcaide, P.
Venue
Cardiovascular Research
Published
2026-06
Volume
122
Issue
9
Pages
1224-1242
ISSN
  • 0008-6363
  • 1755-3245
Cited by
3
References
1
Language
en
Funders
  • National Institute of Health (R01 HL144477, HL165725)
  • Tufts Springboard Tier 1 Grant (HL162200, R01 HL159089, R01 HL133215, HL159907, HL175911, 1187744, R01 HL163172, HL149891, HL105993, R01 HL089847)
  • German Research Foundation
  • Walter Benjamin programme (539486371)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: STING promotes CD8 T-cell cardiotropism and fibrosis from distinct cellular compartments in doxorubicin cardiomyopathy. https://app.cochat.ai/papers/10.1093/cvr/cvag098
The paper
Bayer, A. L., Zambrano, M. A., Emig, R., Sanders, E., Smolgovsky, S., Wagner, N., Bedi, K. C., Bhave, S., Kapur, N. K., Margulies, K. B., Asnani, A., & Alcaide, P. (2026). STING promotes CD8 T-cell cardiotropism and fibrosis from distinct cellular compartments in doxorubicin cardiomyopathy. Cardiovascular Research. https://doi.org/10.1093/cvr/cvag098

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.